VolitionRX

VolitionRX FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of VolitionRX (VNRX) as of Oct 10, 2026 is 84.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.14 % — a change of -13.74% (lower).

FCF Conversion

84.66 %

YoY

-13.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of VolitionRX is 2025 84.66 % . FCF Conversion Rate (FCF/EBITDA) of VolitionRX was 2024 98.14 % . It decreases by -13.74% lower compared to the previous year.

The VolitionRX FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
83.49 USD
Jan 1, 2019
82.31 USD
Jan 1, 2020
90.43 USD
Jan 1, 2021
81.40 USD
Jan 1, 2022
55.66 USD
Jan 1, 2023
54.21 USD
Jan 1, 2024
98.14 USD
Jan 1, 2025
84.66 USD
The VolitionRX FCF Conversion history
YEARFCF ConversionYoY
84.66 %-13.74%
98.14 %+81.04%
54.21 %-2.61%
55.66 %-31.62%
81.40 %-9.99%
90.43 %+9.87%
82.31 %-1.41%
83.49 %-9.46%
92.21 %+15.91%
79.55 %-16.86%
95.68 %+76.85%
54.10 %—
Access this data via the Eulerpool API

VolitionRX Stock analysis

What does VolitionRX do? VolitionRX Ltd was founded in 2010 with headquarters in Austin, Texas. It is a multinational life science company specializing in the discovery of cancer and other disease markers. The company's mission is to improve the quality of life for millions of people worldwide through the development of pain diagnostic systems. History VolitionRX began as a collaboration between scientists Professor Avraham Rasooly from the University of California and Professor David Kroll from North Carolina State University. The two professors were searching for a more effective diagnostic method for cancer and eventually co-founded VolitionRX in 2010. Initially, the company focused on developing diagnostic tests for stomach and colorectal cancer. Business model VolitionRX is a research-based company that specializes in the development of diagnostic and testing systems for cancer. The company works closely with leading cancer experts and scientific institutions to achieve groundbreaking research results. The goal is to develop innovative diagnostic methods that enable doctors to detect cancer faster and more effectively. Divisions VolitionRX is divided into three main areas: diagnostic tests, research and development, and partner and customer relations. Diagnostic tests VolitionRX offers a variety of diagnostic tests for cancer and other diseases. The tests are based on nucleosomics technology, which allows for analysis of cellular DNA. VolitionRX has developed various tests for colorectal cancer, lung cancer, pancreatic cancer, and other types of cancer, and is working on new tests for other conditions. Research and development VolitionRX continuously invests in research and development of new diagnostic methods for cancer and other diseases. The company collaborates closely with leading scientific institutions and cancer experts to develop innovative solutions for cancer diagnostics. Partner and customer relations VolitionRX works with a range of partners to distribute its diagnostic tests worldwide. The company has partnerships with various diagnostic laboratories and medical institutions to make its tests available to a wider target audience. Products VolitionRX offers a variety of products for the diagnosis of cancer and other diseases. These include: 1. NuQ blood tests for the diagnosis of colorectal cancer and other types of cancer. 2. Nucleosomics technology for analysis of cellular DNA for early cancer detection. 3. Software for data analysis from medical tests. Future prospects VolitionRX aims to further improve its technology for cancer diagnosis in order to save lives and improve the quality of life for people worldwide. The company's future prospects are promising as the demand for fast and effective cancer diagnostic methods continues to increase due to the rising number of cancer cases worldwide. VolitionRX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VolitionRX stock

FCF Conversion Rate (FCF/EBITDA) of VolitionRX is 84.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of VolitionRX changed from 98.14 % to 84.66 %, representing a -13.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) VolitionRX since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s VolitionRX with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — VolitionRX

All Key Metrics — VolitionRX